ACTG

Business Context and Reporting Period

Company: Acacia Research Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002

Acacia Research Corporation operates two distinct business groups: the CombiMatrix Group (life sciences, developing biochip technology for genomic and proteomic research) and the Acacia Technologies Group (media technologies, holding patents for Digital Media Transmission and V-chip technology). In December 2002, the company completed a recapitalization, creating two separate classes of common stock to reflect the performance of each group. The company also acquired the remaining 52% of CombiMatrix Corporation, increasing its ownership to 100%.

Key Financial Metrics (Year Ended Dec 31, 2002)

Note: The CombiMatrix Group's net loss includes significant non-cash charges related to litigation settlements and acquired in-process research and development (IPR&D).

Material Changes vs. Prior Period

• Revenue Decline: Consolidated revenues dropped to $0.9 million from $24.6 million in 2001. This was primarily due to the cessation of significant one-time V-chip license fee income in the Acacia Technologies Group ($24.2 million in 2001 vs. $0.04 million in 2002).
• Increased Losses: The consolidated net loss widened to $59.0 million from $22.3 million in 2001. The CombiMatrix Group's loss increased significantly due to a $17.2 million charge for acquired IPR&D and an $18.5 million legal settlement charge.
• Acquisition: Acacia Research acquired the remaining 52% of CombiMatrix Corporation for approximately $46.8 million (fair value of stock issued plus costs), resulting in the expensing of $17.2 million in IPR&D.
• Legal Settlement: CombiMatrix settled litigation with Nanogen, Inc., agreeing to pay $1.0 million in cash and issue shares valued at $17.5 million, recorded as a legal settlement charge.

Guidance, Outlook, and Risks

Management Commentary:

• CombiMatrix Group: The group emerged from the development stage in 2002, generating initial revenues from government grants and product sales. It relies heavily on a strategic alliance with Roche Diagnostics, which has provided $11.5 million in milestone payments (recorded as deferred revenue). Management expects to incur significant losses in the foreseeable future as it continues R&D to commercialize its biochip technology.
• Acacia Technologies Group: The group is transitioning away from its primary revenue source, the V-chip patent, which expires in July 2003. It is actively marketing its Digital Media Transmission (DMT) technology and pursuing litigation against approximately 40 internet content providers for patent infringement.

Key Risks and Contingencies:

• V-Chip Patent Expiration: The Acacia Technologies Group faces a critical revenue cliff as its V-chip patent expires in July 2003. Future revenue depends on the successful licensing of DMT technology.
• Litigation Uncertainty: A September 2002 court ruling found that defendants did not infringe on the V-chip patent. While Acacia intends to appeal, the outcome is uncertain. Additionally, the group has initiated new DMT infringement litigation.
• Liquidity: The company has an accumulated deficit of $159.0 million. While cash balances are currently sufficient for the foreseeable future, the company may need to raise additional capital, which could be dilutive.
• Capital Structure Risks: The two-class stock structure creates potential conflicts of interest and limits the ability of holders of one class to protect their interests against decisions favoring the other group.

Investor Verification Checklist

• V-Chip Revenue Run-Rate: Verify the status of remaining V-chip license collections prior to the July 2003 patent expiration.
• DMT Commercialization: Assess the progress of the Digital Media Transmission licensing program and the status of the pending infringement lawsuits against internet content providers.
• CombiMatrix-Roche Agreement: Review the specific milestones and payment triggers in the amended agreement with Roche Diagnostics to understand future cash flow visibility.
• Legal Settlement Obligations: Confirm the schedule for the remaining $0.5 million cash payment to Nanogen and the potential royalty obligations based on future product sales.
• Capital Requirements: Evaluate the burn rate of the CombiMatrix Group against its current cash position to determine the timeline for potential future equity or debt financing.